Patents by Inventor Dan Michael Weinthal

Dan Michael Weinthal has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240148771
    Abstract: Provided herein are compositions and methods for modifying a predetermined nucleic acid sequence. A programmable nucleoprotein molecular complex containing a polypeptide moiety and a specificity conferring nucleic acid (SCNA) which assembles in-vivo, in a target cell, and is capable of interacting with the predetermined target nucleic acid sequence is provided. The programmable nucleoprotein molecular complex is capable of specifically modifying and/or editing a target site within the target nucleic acid sequence and/or modifying the function of the target nucleic acid sequence.
    Type: Application
    Filed: May 15, 2023
    Publication date: May 9, 2024
    Applicant: TARGETGENE BIOTECHNOLOGIES LTD.
    Inventors: Yoel Moshe SHIBOLETH, Dan Michael WEINTHAL
  • Publication number: 20230220425
    Abstract: The invention provides highly effective and versatile CRISPR/Cas protein variants, compositions, methods and uses thereof in gene editing. More specifically, the invention relates to PAM-reduced or PAM-abolished Cas proteins and chimeras, complexes and conjugates thereof, genetic editing systems and to therapeutic and non-therapeutic methods and uses of the PAM-reduced or PAM-abolished Cas proteins.
    Type: Application
    Filed: October 28, 2020
    Publication date: July 13, 2023
    Inventors: Yoel Moshe SHIBOLETH, Dan Michael WEINTHAL, Devin Lee TRUDEAU, Talya KUNIK, Mati COHEN
  • Patent number: 11690866
    Abstract: Provided herein are compositions and methods for modifying a predetermined nucleic acid sequence. A programmable nucleoprotein molecular complex containing a polypeptide moiety and a specificity conferring nucleic acid (SCNA) which assembles in-vivo, in a target cell, and is capable of interacting with the predetermined target nucleic acid sequence is provided. The programmable nucleoprotein molecular complex is capable of specifically modifying and/or editing a target site within the target nucleic acid sequence and/or modifying the function of the target nucleic acid sequence.
    Type: Grant
    Filed: March 3, 2017
    Date of Patent: July 4, 2023
    Assignee: TARGETGENE BIOTECHNOLOGIES LTD.
    Inventors: Yoel Moshe Shiboleth, Dan Michael Weinthal
  • Patent number: 11458157
    Abstract: Provided herein are compositions and methods for modifying a predetermined nucleic acid sequence. A programmable nucleoprotein molecular complex containing a polypeptide moiety and a specificity conferring nucleic acid (SCNA) which assembles in-vivo, in a target cell, and is capable of interacting with the predetermined target nucleic acid sequence is provided. The programmable nucleoprotein molecular complex is capable of specifically modifying and/or editing a target site within the target nucleic acid sequence and/or modifying the function of the target nucleic acid sequence.
    Type: Grant
    Filed: December 16, 2012
    Date of Patent: October 4, 2022
    Assignee: Targetgene Biotechnologies Ltd.
    Inventors: Yoel Moshe Shiboleth, Dan Michael Weinthal
  • Patent number: 11278560
    Abstract: Provided herein are compositions and methods for modifying a predetermined nucleic acid sequence. A programmable nucleoprotein molecular complex containing a polypeptide moiety and a specificity conferring nucleic acid (SCNA) which assembles in-vivo, in a target cell, and is capable of interacting with the predetermined target nucleic acid sequence is provided. The programmable nucleoprotein molecular complex is capable of specifically modifying and/or editing a target site within the target nucleic acid sequence and/or modifying the function of the target nucleic acid sequence.
    Type: Grant
    Filed: March 3, 2017
    Date of Patent: March 22, 2022
    Assignee: TARGETGENE BIOTECHNOLOGIES LTD.
    Inventors: Yoel Moshe Shiboleth, Dan Michael Weinthal
  • Patent number: 10220052
    Abstract: Provided herein are compositions and methods for modifying a predetermined nucleic acid sequence. A programmable nucleoprotein molecular complex containing a polypeptide moiety and a specificity conferring nucleic acid (SCNA) which assembles in-vivo, in a target cell, and is capable of interacting with the predetermined target nucleic acid sequence is provided. The programmable nucleoprotein molecular complex is capable of specifically modifying and/or editing a target site within the target nucleic acid sequence and/or modifying the function of the target nucleic acid sequence.
    Type: Grant
    Filed: April 28, 2017
    Date of Patent: March 5, 2019
    Assignee: TARGETGENE BIOTECHNOLOGIES LTD
    Inventors: Yoel Moshe Shiboleth, Dan Michael Weinthal
  • Publication number: 20170319613
    Abstract: Provided herein are compositions and methods for modifying a predetermined nucleic acid sequence. A programmable nucleoprotein molecular complex containing a polypeptide moiety and a specificity conferring nucleic acid (SCNA) which assembles in-vivo, in a target cell, and is capable of interacting with the predetermined target nucleic acid sequence is provided. The programmable nucleoprotein molecular complex is capable of specifically modifying and/or editing a target site within the target nucleic acid sequence and/or modifying the function of the target nucleic acid sequence.
    Type: Application
    Filed: March 3, 2017
    Publication date: November 9, 2017
    Inventors: Yoel Moshe SHIBOLETH, Dan Michael WEINTHAL
  • Publication number: 20170233752
    Abstract: Provided herein are compositions and methods for modifying a predetermined nucleic acid sequence. A programmable nucleoprotein molecular complex containing a polypeptide moiety and a specificity conferring nucleic acid (SCNA) which assembles in-vivo, in a target cell, and is capable of interacting with the predetermined target nucleic acid sequence is provided. The programmable nucleoprotein molecular complex is capable of specifically modifying and/or editing a target site within the target nucleic acid sequence and/or modifying the function of the target nucleic acid sequence.
    Type: Application
    Filed: April 28, 2017
    Publication date: August 17, 2017
    Applicant: TARGETGENE BIOTECHNOLOGIES LTD.
    Inventors: Yoel Moshe SHIBOLETH, Dan Michael WEINTHAL
  • Publication number: 20170183687
    Abstract: Provided herein are compositions and methods for modifying a predetermined nucleic acid sequence. A programmable nucleoprotein molecular complex containing a polypeptide moiety and a specificity conferring nucleic acid (SCNA) which assembles in-vivo, in a target cell, and is capable of interacting with the predetermined target nucleic acid sequence is provided. The programmable nucleoprotein molecular complex is capable of specifically modifying and/or editing a target site within the target nucleic acid sequence and/or modifying the function of the target nucleic acid sequence.
    Type: Application
    Filed: March 3, 2017
    Publication date: June 29, 2017
    Inventors: Yoel Moshe SHIBOLETH, Dan Michael WEINTHAL
  • Publication number: 20150211023
    Abstract: Provided herein are compositions and methods for modifying a predetermined nucleic acid sequence. A programmable nucleoprotein molecular complex containing a polypeptide moiety and a specificity conferring nucleic acid (SCNA) which assembles in-vivo, in a target cell, and is capable of interacting with the predetermined target nucleic acid sequence is provided. The programmable nucleoprotein molecular complex is capable of specifically modifying and/or editing a target site within the target nucleic acid sequence and/or modifying the function of the target nucleic acid sequence.
    Type: Application
    Filed: December 16, 2012
    Publication date: July 30, 2015
    Inventors: Yoel Moshe Shiboleth, Dan Michael Weinthal